The medication is commonly used to provide long-term, sustained support for managing conditions where functional stability is needed. The controlled-delivery formulation supports a continuous therapeutic benefit that helps maintain symptomatic stability throughout the day.

The medication is relevant across three therapeutic domains: management of essential hypertension, prevention of Chronic Stable Angina Pectoris and Variant Angina, and rate control in certain supraventricular arrhythmias such as Atrial Fibrillation or Atrial Flutter.

---

Managing Conditions and Providing Benefit

This medication helps with reducing persistently elevated blood pressure, which plays a role in managing the strain on the heart and blood vessels, and contributes to the management of long-term cardiovascular risks. For patients dealing with chest discomfort, it is relevant for easing the frequency and intensity of anginal episodes, which may assist with maintaining functional stability during daily activities.

“It is commonly applied in clinical settings that involve managing symptoms related to both high blood pressure and cardiac discomfort.”

The supported use in stabilizing the ventricular rate when it becomes excessively fast supports general stability and helps ease symptoms related to heightened physiological activity during symptomatic episodes.

---

Quick Fact: Symptomatic Support for Angina and Hypertension

The therapeutic goal is to support continuous symptomatic management in chronic conditions, assisting with maintaining functional stability and easing the overall symptom load for conditions characterized by heightened physiological stress.

Eligibility Map: Who can and cannot use Cardizem CD — official regulatory information

---

Eligibility scope

Populations for whom use is allowed (as stated in label): Adults with appropriate indication (e.g., Hypertension, Angina).

Populations for whom use is not recommended (if applicable): Pediatric patients (safety and effectiveness have not been established by regulators).

Populations for whom use is contraindicated:

• Patients with Sick Sinus Syndrome or Second- or Third-Degree Atrioventricular (AV) Block (unless a functioning ventricular pacemaker is present).
• Patients with Severe Hypotension (systolic blood pressure typically below 90 mmHg).
• Patients experiencing Acute Myocardial Infarction (AMI) with Pulmonary Congestion.
• Patients with known hypersensitivity to diltiazem hydrochloride or any component of the capsule.

---

Age-related eligibility rules

• Pediatric Patients: Use is not established and generally not recommended by regulatory agencies.
• Older Adults (Geriatric): Clinical data is insufficient to determine differential responses; the label advises dosing should generally start at the low end of the range.

---

Condition-specific eligibility rules

• Hepatic or Renal Impairment: Use requires caution and close monitoring due to the drug’s metabolism and excretion.
• Left Ventricular Dysfunction (Heart Failure): Use requires caution as the label warns about potential for worsening ventricular function.
• Acute Porphyria: The medicine is deemed unsafe for use by some international regulators.

---

Pregnancy and lactation eligibility status

• Pregnancy: Categorized as US FDA Pregnancy Category C; use is only permitted if the potential benefit justifies the potential risk to the fetus.
• Lactation (Breastfeeding): Diltiazem is excreted in human milk. Nursing should be interrupted, or the drug should be discontinued.

---

Connection to the overall eligibility profile

Official regulatory documents establish a strict eligibility profile defined by absolute contraindications for specific cardiac conduction disorders and hemodynamic instability. Use is restricted to caution for organ impairment and heart failure, and the drug is not established for the pediatric population.

Interactions with other medicines and products

Cardizem CD (diltiazem) is both a substrate and inhibitor of the cytochrome P-450 3A4 ( CYP3A4) enzyme system. This metabolic property is the basis for numerous significant drug interactions. Concomitant use with other medicinal products is subject to specific constraints officially mandated in regulatory labeling.

---

Interacting Medicinal Product Categories and Constraints

Category	Interaction Mechanism and Constraint
Agents Affecting Cardiac Function (e.g., Beta-blockers, Digitalis)	Additive effects on cardiac contractility and/or conduction. Caution and careful titration are warranted.
CYP3A4 Substrates (e.g., Simvastatin, Lovastatin, Midazolam)	Diltiazem is a CYP3A4 inhibitor, which significantly increases the substrate's systemic exposure. Dosage adjustments and close monitoring are necessary. For Simvastatin, the daily dose must be limited to 10 mg when co-administered.
CYP3A4 Inducers (e.g., Rifampin, certain Anticonvulsants)	Inducers may decrease diltiazem plasma levels, potentially reducing its therapeutic effect. Avoidance or close monitoring is generally required.
H2-Receptor Antagonists (e.g., Cimetidine)	Cimetidine may increase diltiazem plasma levels. Patients should be monitored for increased effects and dose adjustments considered.
Alcohol	Alcohol increases the drug's release rate in vitro, which may lead to rapid absorption and increased systemic exposure. Avoid consumption of alcohol with Cardizem CD.

---

Official Interaction Statements

Official labeling specifically identifies Clonidine, Cyclosporine, and Carbamazepine as interacting medicines requiring careful monitoring or dose management. Patients with renal and/or hepatic impairment who are taking other CYP3A4 substrates may require specialized dosage adjustment when diltiazem is started or stopped.

Cardizem CD (diltiazem) acts as an antagonist that specifically targets L-type Voltage-Dependent Calcium Channels (L-VDCCs). This mechanism addresses the fundamental ion flux required for both electrical activity and muscle contraction across the cardiovascular system.

Modulation of Cardiac Electrical Activity and Rate

By blocking L-VDCCs on specialized conductive tissue, primarily the Sinoatrial (SA) and Atrioventricular (AV) nodes, diltiazem delays electrical signal transmission and slows the rate of impulse generation. This results in a decreased heart rate (negative chronotropy) and slowed conduction velocity (negative dromotropy).

Regulation of Vascular and Myocardial Contraction

Inhibiting calcium entry into Vascular Smooth Muscle Cells (VSMCs) causes smooth muscle relaxation, leading to vasodilation and a reduction in systemic vascular resistance (afterload). Simultaneously, this blockade reduces the force of heart contraction (negative inotropy). These systemic and local actions modulate cardiac function, resulting in a reduction of the mechanical workload and oxygen consumption of the myocardium.

Administration Scope

Cardizem CD is an Extended-Release Capsule formulated for oral administration. This controlled-delivery (CD) design supports a single once-daily dosing regimen to ensure continuous therapeutic exposure over 24 hours. The medication may be taken with or without food, as its absorption is not significantly affected by meals.

---

Official Administration Guidelines

The general principle for administration is to swallow the capsule whole. It is a mandatory procedural constraint that the capsule must not be crushed, chewed, or cut to preserve the essential extended-release mechanism. For individuals unable to swallow the whole capsule, the contents may be opened and sprinkled onto a spoonful of applesauce and consumed immediately, followed by water.

Initial adult dosing for hypertension typically begins at 180 mg to 240 mg once daily, while the starting dose for managing angina is generally 120 mg to 180 mg once daily. Dosage adjustments, if required, are carried out over a 7 to 14 day period, which is necessary for the medication to reach its full steady-state therapeutic effect. The maximum labeled dose studied for chronic use is generally 480 mg once daily.

---

Use in Specific Populations

The safety and effectiveness of Cardizem CD have not been established in pediatric patients, and specific use requires caution with careful dose management for older adults or those with hepatic or renal impairment. If a dose is missed, patients are generally instructed to skip the dose if it is near the time for the next scheduled dose, and not to double up.

Research Evidence / Overview of Studies for Cardizem CD

Evidence for Use in Hypertension (High Blood Pressure)

Research has studied Cardizem CD in adults with high blood pressure, including those who are considered elderly and individuals with some co-existing health conditions. These studies have primarily taken the form of Randomized Controlled Trials (RCTs) and open-label trials. The researchers focused on monitoring changes in systolic and diastolic blood pressure readings.

Research reports patterns of change observed during the study period, which contribute to the broader evidence landscape for blood pressure research. The follow-up durations were typically short-term to intermediate-term.

What remains uncertain is the full picture of long-term outcomes, as follow-up durations were limited in the primary efficacy studies. Data for certain groups, such as those with severe or resistant forms of hypertension, remain insufficient for comprehensive conclusions.

---

Evidence for Use in Chronic Stable Angina

Cardizem CD was evaluated in controlled clinical trials and crossover studies for chronic stable angina (chest pain related to the heart). These studies primarily focused on outcomes related to physical discomfort during exercise.

Research examined outcomes such as the patient's time to onset of angina symptoms during a controlled exercise test. These findings describe patterns observed in the studies related to measured outcomes during exercise testing. Long-term effects are not fully established regarding the sustained impact on cardiovascular events over many years.

---

Long-Term Studies and Follow-up

Most primary research had limited follow-up durations. This means that while research reports short-term measured changes, long-term effects are not fully established by these core studies. Data for evaluating the durability of response and the sustained impact on major cardiovascular events over many years remain limited.

---

Evidence in Special Populations and Comorbidities

Cardizem CD was studied for use in certain special populations, such as older adults with hypertension. A single study monitored measured outcomes related to how the drug is handled by the body in patients with severely impaired kidney function and reported that they were observed to be similar to those in patients with normal kidney function. However, data for certain groups remain insufficient, such as for pregnant populations or children.

---

What is Still Uncertain About Cardizem CD

The long-term effects are not fully established for many outcomes. Evidence quality varies across studies, and findings were mixed or inconsistent in some specific subgroups. Sample sizes were modest in some of the subgroup analyses. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Common questions about Cardizem CD (FAQ)

Q: What is Cardizem CD (diltiazem) and how does it work?

Cardizem CD is a brand of diltiazem hydrochloride that is used to treat high blood pressure (hypertension) and to manage chronic stable angina (a type of chest pain). It belongs to a class of medications called calcium channel blockers.

It works by:

• Relaxing blood vessels, which lowers blood pressure and makes it easier for the heart to pump blood throughout the body.
• Increasing the supply of blood and oxygen to the heart, which helps to prevent chest pain.

Q: How should I take Cardizem CD capsules?

Always follow your doctor's instructions exactly.

• Cardizem CD is an extended-release capsule that is typically taken once a day.
• Try to take it at the same time each day.
• Swallow the capsule whole. Do not chew, break, or crush the capsule, as this can affect the way the medicine works and may increase the risk of side effects.
• Your doctor or pharmacist can advise you on whether to take this medication with or without food, as instructions may vary based on the specific product.

Q: What should I do if I miss a dose of Cardizem CD?

• Take the missed dose as soon as you remember.
• If it is almost time for your next scheduled dose, skip the missed dose and go back to your regular dosing schedule.
• Do not take a double dose or extra doses to make up for the missed one.

Q: What are the possible side effects of Cardizem CD?

Some common side effects may include:

• Swelling (edema)
• Headache
• Dizziness or lightheadedness
• Facial flushing
• Constipation

Contact your healthcare professional right away if you experience signs of a severe allergic reaction, such as a rash, itching, hives, or swelling of the face, lips, tongue, or throat. You should also tell your doctor if you experience severe dizziness, fainting spells, or an unusually slow heartbeat.

Q: What precautions should I take while using Cardizem CD?

• Tell all of your healthcare providers, including doctors, dentists, and pharmacists, that you are taking Cardizem CD.
• Cardizem CD may cause dizziness or lightheadedness. Avoid driving or operating machinery until you know how this medication affects you.
• To reduce the chance of dizziness or fainting, rise slowly from a sitting or lying position.
• Grapefruit juice may affect the amount of diltiazem in your body; talk to your doctor about this potential interaction.
• Do not stop taking Cardizem CD without first talking to your doctor, even if you feel well. Suddenly stopping this medicine may cause your condition to worsen.

Cardizem CD (diltiazem hydrochloride extended-release capsules) must be stored and disposed of according to specific conditions mandated by regulatory labeling.

---

Required Storage Conditions

The medication must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). It must be protected from light, moisture, and excessive heat, and should be kept from freezing. The capsules must remain in the original container, which should be tightly closed to maintain product integrity. For safety, it is required to keep the medication out of the reach of children.

---

Official Disposal Instructions

Expired or unused Cardizem CD should be disposed of through a medicine take-back program. If one is unavailable, it should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container before disposal in the household trash. The product must not be flushed down the toilet.